Acute therapies and disease-modifying therapies for multiple sclerosis

Khurram Bashir, Dean M. Wingerchuk

Research output: Chapter in Book/Report/Conference proceedingChapter


Multiple sclerosis (MS) is an inflammatory demyelinating CNS disease for which several immunomodulatory and immunosuppressive strategies have been shown to reduce evidence of disease activity and preserve neurological function. High-dose parenteral corticosteroid therapy speeds recovery from acute attacks of MS, including optic neuritis. Severe, corticosteroid-refractory attacks may respond to plasma exchange. Following a first-ever demyelinating event (clinically isolated syndrome), treatment with glatiramer acetate, intramuscular interferon ß-1a, or subcutaneous interferon ß-1b reduces the risk of the development of clinically definite MS over the subsequent 2–3 years.

Original languageEnglish (US)
Title of host publicationNeurology
Subtitle of host publicationAn Evidence-Based Approach
PublisherSpringer New York
Number of pages19
ISBN (Electronic)9780387885551
ISBN (Print)9780387885544
StatePublished - Jan 1 2012


  • Clinically isolated syndrome
  • Diagnosis
  • Disease modifying therapy
  • Epidemiology
  • Evidence-based medicine
  • Multiple sclerosis
  • Optic neuritis
  • Prognosis
  • Treatment

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Acute therapies and disease-modifying therapies for multiple sclerosis'. Together they form a unique fingerprint.

Cite this